SCHEMBL7147121

SCHEMBL7147121

COc1ccc(S(=O)(=O)N(c2cccc(OC)c2)[C@@H]2CCN(Cc3ccccc3)C[C@@H]2C)cc1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.49
ALDH1A1 P00352 2/20 0.47
LMNA P02545 1/20 0.46
SIGMAR1 Q99720 2/20 0.44
MMP1 P03956 2/20 0.44
MMP9 P14780 2/20 0.44
MMP13 P45452 2/20 0.44
MMP3 P08254 1/20 0.44
MMP7 P09237 1/20 0.44
KMT2A Q03164 2/20 0.44
CHRM2 P08172 1/20 0.43
CHRM3 P20309 1/20 0.43
KDM4E B2RXH2 1/20 0.42
OPRM1 P35372 1/20 0.42
HRH2 P25021 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7255077 0.93 ALDH1A1 (0.51) ACHEALDH1A1LMNASIGMAR1MMP1
SCHEMBL7253074 0.93 ALDH1A1 (0.51) ACHEALDH1A1LMNASIGMAR1MMP1
SCHEMBL7255870 0.93 ALDH1A1 (0.51) ACHEALDH1A1LMNASIGMAR1MMP1
SCHEMBL7164480 0.86 ACHE (0.55) ACHEALDH1A1LMNASIGMAR1KMT2A
SCHEMBL7176795 0.81 ALDH1A1 (0.51) ACHEALDH1A1LMNASIGMAR1CHRM2
SCHEMBL7167878 0.80 ALDH1A1 (0.49) ACHEALDH1A1LMNASIGMAR1KMT2A
SCHEMBL7168742 0.79 CHRM2 (0.51) ACHEALDH1A1LMNASIGMAR1KMT2A
SCHEMBL7256653 0.79 LMNA (0.59) ACHEALDH1A1LMNASIGMAR1MMP1
SCHEMBL7139282 0.79 ACHE (0.49) ACHEALDH1A1LMNACHRM2CHRM3
SCHEMBL7166368 0.79 ALDH1A1 (0.52) ACHEALDH1A1LMNASIGMAR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176461-A1 Aminopiperidines NPS ALLELIX CORP. (CANADA CORPORATION) (CA) 2003-09-18 US claimed
EP-1296950-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS Allelix Corp. (CA) 2003-04-02 EP claimed
WO-2001081308-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS ALLELIX CORP. (CA) 2001-11-01 WO claimed
US-20030176461-A1 Aminopiperidines NPS ALLELIX CORP. (CANADA CORPORATION) (CA) 2003-09-18 US disclosed
EP-1296950-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS Allelix Corp. (CA) 2003-04-02 EP disclosed
WO-2001081308-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS ALLELIX CORP. (CA) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176461-A1 Aminopiperidines SLC1A2, SLC6A4, SLC1A1 ACHE 826/4885ALDH1A1 1218/4885LMNA 2941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.